Stocks›Healthcare›LENZ

LENZ

LENZ THERAPEUTICS, INC.

NasdaqResearch view

$3.92+5.24%

Sep 25 close · 1D EOD · Databento

HealthcareBiological Products, (No Diagnostic Substances)Micro-capSEC EDGAR FY 2025-12-31

What happened

Daily closes · dots are Wire stories

What’s next

Expected around early November, going by its own filing history. The company has not announced a date yet. Its matching report came Nov 5, 2025 and Nov 6, 2024, after the close.

Last report

Aug 11, 2026−3.26%

after the close

Last 4, next close

median 12.23% either way

up 0 of 4

Every report since 2022 →

DateEventSourceNext close

Aug 11Earnings release, after the close · 8-KSEC EDGARSEC EDGAR ↗−3.26%

Next close = the first close after the event against the close before it. Prior-session closes only; not a call, not advice.

Big days · last year

Daily closes · Databento EOD

17 big days: a close more than 8.63% from the one before, three times LENZ’s median day (2.88%). On 0 of 17, its largest peers moved the same way at least half as far. We show what we hold, never a cause.

Shaded: since our stories began, Jun 10, 2026

17Sep 23, 2026
Sep 23, 2026Nothing in our recordNo LENZ story, brief or results filing in our record that dayGroup −0.6% did not move with it
−0.6% did not move with itAMGN −1.0 · BIIB +1.0 · GILD −0.8 · MRNA −0.3
−8.96%
16Sep 8, 2026
Sep 8, 2026Nothing in our recordNo LENZ story, brief or results filing in our record that dayGroup −3.7% did not move with it
−3.7% did not move with itAMGN −10.1 · BIIB −3.8 · MRNA −3.6 · GILD −2.9
−10.57%
15Sep 2, 2026
Sep 2, 2026Nothing in our recordNo LENZ story, brief or results filing in our record that dayGroup +0.4% did not move with it
+0.4% did not move with itBIIB +3.1 · MRNA −2.2 · AMGN +1.1 · GILD −0.2
+10.90%
14Aug 13, 2026
Aug 13, 2026Nothing in our recordNo LENZ story, brief or results filing in our record that dayGroup +0.6% did not move with it
+0.6% did not move with itGILD +1.7 · BIIB +0.8 · AMGN +0.4 · MRNA −0.0
−8.73%
13May 14, 2026
May 14, 2026Before our storiesGroup −0.8% did not move with it
−0.8% did not move with itBIIB −6.4 · MRNA −0.8 · GILD −0.7 · AMGN −0.1
−9.44%
12May 12, 2026
May 12, 2026ResultsThe first close after a results filing (SEC 8-K, Item 2.02)Group +0.9% did not move with it
+0.9% did not move with itAMGN +2.0 · GILD +1.1 · MRNA +0.7 · BIIB +0.7
−20.82%
11Mar 31, 2026
Mar 31, 2026Before our storiesGroup +1.5% did not move with it
+1.5% did not move with itMRNA +5.3 · BIIB −2.3 · GILD +2.2 · AMGN +0.8
+10.37%
10Mar 24, 2026
Mar 24, 2026ResultsThe first close after a results filing (SEC 8-K, Item 2.02)Group +0.1% did not move with it
+0.1% did not move with itGILD +0.6 · AMGN −0.4 · BIIB +0.2 · MRNA +0.1
−17.91%
9Mar 20, 2026
Mar 20, 2026Before our storiesGroup −1.5% did not move with it
−1.5% did not move with itGILD −2.8 · MRNA −1.9 · BIIB −1.1 · AMGN −0.6
−8.79%
8Jan 30, 2026
Jan 30, 2026Before our storiesGroup +0.7% did not move with it
+0.7% did not move with itMRNA −6.0 · BIIB +2.1 · GILD +1.7 · AMGN −0.3
−11.02%
7Jan 22, 2026
Jan 22, 2026Before our storiesGroup +1.3% did not move with it
+1.3% did not move with itMRNA +4.1 · GILD +1.6 · AMGN +1.0 · BIIB +0.7
+9.19%
6Jan 14, 2026
Jan 14, 2026Before our storiesGroup +1.7% did not move with it
+1.7% did not move with itBIIB −5.0 · MRNA +2.5 · GILD +1.9 · AMGN +1.4
+11.99%
5Dec 12, 2025
Dec 12, 2025Before our storiesGroup −0.2% did not move with it
−0.2% did not move with itGILD −2.3 · BIIB +0.9 · MRNA −0.6 · AMGN +0.1
−25.96%
4Dec 2, 2025
Dec 2, 2025Before our storiesGroup −0.0% did not move with it
−0.0% did not move with itBIIB +1.4 · MRNA −0.4 · GILD −0.3 · AMGN +0.3
−10.16%
3Nov 11, 2025
Nov 11, 2025Before our storiesGroup +4.2% did not move with it
+4.2% did not move with itMRNA +6.7 · AMGN +4.6 · GILD +3.7 · BIIB +2.1
+14.06%
2Nov 5, 2025
Nov 5, 2025ResultsThe first close after a results filing (SEC 8-K, Item 2.02)Group +1.2% did not move with it
+1.2% did not move with itAMGN +7.8 · BIIB +2.8 · MRNA −0.8 · GILD −0.3
−23.46%
1Oct 10, 2025
Oct 10, 2025Before our storiesGroup −1.9% did not move with it
−1.9% did not move with itMRNA −2.5 · BIIB −2.0 · AMGN −1.8 · GILD +0.4
−16.13%

A story on the same day is not a cause, and a group move is not proof either. Group: AMGN, GILD, MRNA, BIIB, the largest companies in LENZ’s SEC industry; “the same way” means the same direction and at least half as far. Prior-session closes only; not a call, not advice.

The numbers · FY2025, filed

SEC EDGAR

Market cap$123M

Revenue$19.1M

Net income$-82.1M

EPS, diluted$-2.85−21.80%

Operating margin-477.5%

Return on equity-28.9%

All filed figures

Snapshot

SEC EDGAR · FY 2025-12-31

SectorHealthcare

Market Cap$123.0M

Enterprise Value$97.8M

Income$-82.1M

Sales$19.1M

Book/sh$9.05

Cash/sh$0.80

Dividend TTM—

Payout—

Employees—

IPO—

Quick Ratio14.09

Current Ratio14.23

Debt/Eq—

EPS (ttm)$-2.85

EPS this Y-21.8%

EPS past 3/5Y—

Sales past 3/5Y—

EPS Y/Y TTM-21.8%

Sales Y/Y TTM—

Shs Outstand31.42M

ROA-26.8%

ROE-28.9%

ROIC-35.4%

Gross Margin—

Oper. Margin-477.5%

Profit Margin-430.3%

Every figure here is filed with the SEC. Valuation and estimate metrics (P/E, PEG, EV/EBITDA, price targets, forward EPS) are omitted until our market-data feed is licensed for display — we’d rather show fewer numbers than blank ones. Deeper lines (cash flow, balance sheet) below.

Revenue by fiscal year

FY24

$19.1M

FY25

Financials, annual · income and cash flowSEC EDGAR · open ▸

Financials — annual

SEC EDGAR · last 2 FY · tap a row to explain it

USD	FY2024	FY2025
Revenue	$0	$19.1M
Gross Profit	—	—
Operating Income	$-58.6M	$-91.1M
Net Income	$-49.8M	$-82.1M
Diluted EPS	$-2.34	$-2.85
Operating Cash Flow	$-59.4M	$-69.2M
Free Cash Flow	$-59.9M	$-70.0M

Same industry

In the screener →

AMGN$224.2B GILD$187.1B MRNA$79.4B BIIB$33.6B EXEL$14.4B NBIX$14.1B HALO$12.9B TWST$11.5B

Build basket with LENZ Screener

Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.